Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 8, 2012 - Issue 8: Special Focus: Cancer Commentary Series. Guest Editors: Michael G. Hanna and Alex Kudrin
Submit an article Journal homepage
2,040
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

Size of clinical trials and Introductory prices of prophylactic vaccine series

Steven H. Weinberg Child Health Evaluation and Research (CHEAR) Unit; Division of General Pediatrics; University of Michigan; Ann Arbor, MI USA
,
Amy T. Butchart Child Health Evaluation and Research (CHEAR) Unit; Division of General Pediatrics; University of Michigan; Ann Arbor, MI USA
&
Matthew M. Davis Child Health Evaluation and Research (CHEAR) Unit; Division of General Pediatrics; University of Michigan; Ann Arbor, MI USA; Division of General Medicine and Gerald R. Ford School of Public Policy; University of Michigan; Ann Arbor, MI USACorrespondence[email protected]
Pages 1066-1070 | Received 27 Jan 2012, Accepted 16 Apr 2012, Published online: 01 Aug 2012

References

  • Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JRC, Pok A, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 2010; 28:1353 - 6; http://dx.doi.org/10.1016/j.vaccine.2009.11.007; PMID: 19932670
  • Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011; 60:619 - 23; PMID: 21597455
  • Centers for Disease Control and Prevention (CDC). Ten great public health achievements--United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999; 48:241 - 3; PMID: 10220250
  • Davis MM, Zimmerman JL, Wheeler JRC, Freed GL. Childhood vaccine purchase costs in the public sector: past trends, future expectations. Am J Public Health 2002; 92:1982 - 7; http://dx.doi.org/10.2105/AJPH.92.12.1982; PMID: 12453820
  • Davis MM. Price as a double-edged sword in the golden era of vaccines. Hum Vaccin 2010; 6:689 - 93; http://dx.doi.org/10.4161/hv.6.9.13496; PMID: 20930511
  • Kim JJ. The role of cost-effectiveness in U.S. vaccination policy. N Engl J Med 2011; 365:1760 - 1; http://dx.doi.org/10.1056/NEJMp1110539; PMID: 22010866
  • Lindley MC, Shen AK, Orenstein WA, Rodewald LE, Birkhead GS. Financing the delivery of vaccines to children and adolescents: challenges to the current system. Pediatrics 2009; 124:Suppl 5 S548 - 57; http://dx.doi.org/10.1542/peds.2009-1542O; PMID: 19948587
  • Institute of Medicine. Financing vaccines in the 21st century: assuring access and availability. Washington, DC: National Academies Press; 2003.
  • Smith PJ, Lindley MC, Rodewald LE. Vaccination coverage amongst US children aged 19-35 months entitled by the Vaccines for Children program, 2009. Public Health Rep 2001; 126:Supplement 2 109 - 23
  • Sloan FA, Berman S, Rosenbaum S, Chalk RA, Giffin RB. The fragility of the U.S. vaccine supply. N Engl J Med 2004; 351:2443 - 7; http://dx.doi.org/10.1056/NEJMsb033394; PMID: 15575064
  • US Congress Office of Technology Assessment. Pharmaceutical R&D: costs risks and rewards. Washington, DC: US Government Printing Office; 1993.
  • Ellenberg SS. Safety considerations for new vaccine development. Pharmacoepidemiol Drug Saf 2001; 10:411 - 5; http://dx.doi.org/10.1002/pds.616; PMID: 11802587
  • DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87:272 - 7; http://dx.doi.org/10.1038/clpt.2009.295; PMID: 20130567
  • US National Institutes of Health ClinicalTrials. gov. Understanding clinical trials. Bethesda, MD: National Library of Medicine; 2007-2011. Available from http://clinicaltrials.gov/ct2/info/understand
  • Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars?. Health Aff (Millwood) 2006; 25:420 - 8; http://dx.doi.org/10.1377/hlthaff.25.2.420; PMID: 16522582
  • Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin Pharmacol Ther 2011; 89:183 - 8; http://dx.doi.org/10.1038/clpt.2010.286; PMID: 21191382
  • Klein JO, Myers MG. Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply. Pediatrics 2006; 117:2269 - 75; http://dx.doi.org/10.1542/peds.2005-2427; PMID: 16740872
  • US Department of Health and Human Services Food and Drug Administration. Complete list of vaccines licensed for immunization and distribution in the US. Silver Spring, MD: Available from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833
  • US Department of Health and Human Services Center for Disease Control and Prevention. Vaccines for Children: CDC vaccine price list archives. Atlanta, GA. Available from http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list-archives.htm
  • US Department of Labor Bureau of Labor Statistics. Consumer price index inflation calculator. Washington, DC. Available from http://www.bls.gov/data/inflation_calculator.htm
  • Jacobson RM, Adegbenro A, Pankratz VS, Poland GA. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001; 19:2428 - 33; http://dx.doi.org/10.1016/S0264-410X(00)00467-9; PMID: 11257373
  • US Food and Drug Administration. Biologics license application process. Rockville, MD: US Department of Health and Human Services.
  • Honig P, Lalonde R. The economics of drug development: a grim reality and a role for clinical pharmacology. Clin Pharmacol Ther 2010; 87:247 - 51; http://dx.doi.org/10.1038/clpt.2009.298; PMID: 20160740

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.